Enhanced apoptosis and mitochondrial cell death by paclitaxel-loaded TPP-TPGS₁₀₀₀-functionalized nanoemulsion

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Medina MA, Oza G, Sharma A et al. Triple-negative breast cancer: a review of conventional and advanced therapeutic strategies. Int. J. Environ. Res. Public Health 17(6), 1–32 (2020).
  Google Scholar
• 2. Casais-Molina ML, Cab C, Canto G, Medina J, Tapia A. Carbon nanomaterials for breast cancer treatment. J. Nanomater. 2018, 9 (2018).
  Google Scholar
• 3. Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G. Nanotechnology in cancer therapy. J. Drug Target. 21(10), 904–913 (2013).
  Medline CASGoogle Scholar
• 4. Zhou J, Zhao WY, Ma X et al. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials 34(14), 3626–3638 (2013). • Highlights conjugate synthesis.
  Medline CASGoogle Scholar
• 5. Nehate C, Jain S, Saneja A et al. Paclitaxel formulations: challenges and novel delivery options. Curr. Drug Deliv. 11(6), 666–686 (2014).
  Medline CASGoogle Scholar
• 6. Lu RM, Chen MS, Chang DK et al. Targeted drug delivery systems mediated by a novel peptide in breast cancer therapy and imaging. PLOS ONE 8(6), 66128 (2013).
  Medline CASGoogle Scholar
• 7. Duhem N, Danhier F, Préat V. Vitamin E-based nanomedicines for anti-cancer drug delivery. J. Control. Rel. 182(1), 33–44 (2014).
  Medline CASGoogle Scholar
• 8. Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat. Commun. 9(1), 1–12 (2018).
  MedlineGoogle Scholar
• 9. Jurj A, Braicu C, Pop LA, Tomuleasa C, Gherman CD, Berindan-Neagoe I. The new era of nanotechnology–an alternative to change cancer treatment. Drug Des. Devel. Ther. 11, 2871–2890 (2017).
  Medline CASGoogle Scholar
• 10. Jabir NR, Tabrez S, Ashraf GM, Shakil S, Damanhouri GA, Kamal MA. Nanotechnology-based approaches in anticancer research. Int. J. Nanomed. 7, 4391–4408 (2012).
  Medline CASGoogle Scholar
• 11. Afzal M, Ameeduzzafar, Alharbi KS et al. Nanomedicine in treatment of breast cancer – a challenge to conventional therapy. Semin. Cancer Biol. 69(November), 279–292 (2019).
  MedlineGoogle Scholar
• 12. Huwyler J, Drewe J, Krähenbühl S. Tumor targeting using liposomal antineoplastic drugs. Int. J. Nanomed. 3(1), 21–29 (2008).
  CASGoogle Scholar
• 13. Ren F, Jing Q, Cui J, Shen Y. Synthesis and characterization of D-α-tocopheryl polyethylene glycol 1000 succinate-block-poly (ε-caprolactone) copolymer used as carriers for microparticles. J. Dispers. Sci. Technol. 30(8), 1129–1134 (2009).
  CASGoogle Scholar
• 14. Tan S, Zou C, Zhang W, Yin M, Gao X, Tang Q. Recent developments in d-α-tocopheryl polyethylene glycol-succinate-based nanomedicine for cancer therapy. Drug Deliv. 24(1), 1831–1842 (2017).
  Medline CASGoogle Scholar
• 15. Choudhury H, Gorain B, Pandey M et al. Recent advances in TPGS-based nanoparticles of docetaxel for improved chemotherapy. Int. J. Pharm. 529(1–2), 506–522 (2017).
  Medline CASGoogle Scholar
• 16. Wee Gan C, Feng S-S. Transferrin-conjugated nanoparticles of poly(lactide)-d-α-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials 31(30), 7748–7757 (2010).
  MedlineGoogle Scholar
• 17. Pan J, Feng SS. Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. Biomaterials 29(17), 2663–2672 (2008).
  Medline CASGoogle Scholar
• 18. Zhang S, Li J, Hu S, Wu F, Zhang X. Triphenylphosphonium and D-α-tocopheryl polyethylene glycol 1000 succinate-modified, tanshinone IIA-loaded lipid-polymeric nanocarriers for the targeted therapy of myocardial infarction. Int. J. Nanomed. 13, 4045–4057 (2018).
  Medline CASGoogle Scholar
• 19. Zhang Y, Zhang C, Chen J et al. Trackable mitochondria-targeting nanomicellar loaded with doxorubicin for overcoming drug resistance. ACS Appl. Mater. Interfaces 9(30), 25152–25163 (2017).
  Medline CASGoogle Scholar
• 20. Zhang Y, Shen Y, Teng X, Yan M, Bi H, Morais PC. Mitochondria-targeting nanoplatform with fluorescent carbon dots for long time imaging and magnetic field-enhanced cellular uptake. ACS Appl. Mater. Interfaces 7(19), 10201–10212 (2015).
  Medline CASGoogle Scholar
• 21. Olusanya TOB, Ahmad RRH, Ibegbu DM, Smith JR, Elkordy AA. Liposomal drug delivery systems and anticancer drugs. Molecules 23(4), 1–17 (2018).
  Google Scholar
• 22. Yamada Y, Harashima H. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv. Drug Deliv. Rev. 60(13–14), 1439–1462 (2008).
  Medline CASGoogle Scholar
• 23. Zielonka J, Joseph J, Sikora A et al. Mitochondria-targeted triphenylphosphonium-based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem. Rev. 117(15), 10043–10120 (2017).
  Medline CASGoogle Scholar
• 24. Collnot E-M, Baldes C, Wempe MF et al. Mechanism of inhibition of p-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol. Pharm. 4(3), 465–474 (2007).
  Medline CASGoogle Scholar
• 25. Modica-Napolitano JS, Weissig V, Ross JM, Coppotelli G. Treatment strategies that enhance the efficacy and selectivity of mitochondria-targeted anticancer agents. Int. J. Mol. Sci 16, 16 (2015).
  Google Scholar
• 26. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int. J. Pharm. 235(1–2), 179–192 (2002).
  Medline CASGoogle Scholar
• 27. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37(13), 1590–1598 (2001).
  Medline CASGoogle Scholar
• 28. Gradishar WJ. Taxanes for the treatment of metastatic breast cancer. Breast Cancer Basic Clin. Res. 4(3), 6–159 (2012).
  Google Scholar
• 29. Surapaneni MS, Das SK, Das NG. Designing paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges. Int. Sch. Res. Netw. ISRN Pharmacol. 2012, 15 (2012).
  Google Scholar
• 30. Varbiro G, Veres B, Gallyas F, Sumegi B. Direct effect of Taxol on free radical formation and mitochondrial permeability transition. Free Radic. Biol. Med. 31(4), 548–558 (2001).
  Medline CASGoogle Scholar
• 31. Cuchelkar V, Kopečková P, Kopeček J. Novel HPMA copolymer-bound constructs for combined tumor and mitochondrial targeting. Mol. Pharm. 5(5), 776–786 (2008).
  Medline CASGoogle Scholar
• 32. Singh Y, Viswanadham KKDR, Pawar VK et al. Induction of mitochondrial cell death and reversal of anticancer drug resistance via nanocarriers composed of a triphenylphosphonium derivative of tocopheryl polyethylene glycol succinate. Mol. Pharm. 16(9), 3744–3759 (2019). • Describes strategies for confocal microscopy.
  Medline CASGoogle Scholar
• 33. Pawar A, Patel R, Arulmozhi S, Bothiraja C. D-α-tocopheryl polyethylene glycol 1000 succinate conjugated folic acid nanomicelles: towards enhanced bioavailability, stability, safety, prolonged drug release and synergized anticancer effect of plumbagin. RSC Adv. 6(81), 78106–78121 (2016).
  CASGoogle Scholar
• 34. Wei Z, Hao J, Yuan S et al. Paclitaxel-loaded pluronic P123/F127 mixed polymeric micelles: formulation, optimization and in vitro characterization. Int. J. Pharm. 376(1–2), 176–185 (2009).
  Medline CASGoogle Scholar
• 35. Gaisford S, Beezer AE, Mitchell JC. Diode-array UV spectrometric evidence for cooperative interactions in binary mixtures of pluronics F77, F87 and F127. Langmuir 13(10), 2606–2607 (1997).
  CASGoogle Scholar
• 36. Meher JG, Dixit S, Singh Y et al. Paclitaxel-loaded colloidal silica and TPGS-based solid self-emulsifying system interferes Akt/mTOR pathway in MDA-MB-231 and demonstrates anti-tumor effect in syngeneic mammary tumors. AAPS PharmSciTech 21(8), 313 (2020). • Describes Box–Behnken design approaches.
  Medline CASGoogle Scholar
• 37. Ahmed S, Gull A, Alam M, Aqil M, Sultana Y. Ultrasonically tailored, chemically engineered and “QbD” enabled fabrication of agomelatine nanoemulsion; optimization, characterization, ex-vivo permeation and stability study. Ultrason. Sonochem. 41, 213–226 (2018).
  Medline CASGoogle Scholar
• 38. Singh Y, Ojha P, Srivastava M, Chourasia MK. Reinvestigating nanoprecipitation via Box-Behnken design: a systematic approach. J. Microencapsul. 32(1), 75–85 (2015).
  Medline CASGoogle Scholar
• 39. Pawar VK, Panchal SB, Singh Y et al. Immunotherapeutic vitamin E nanoemulsion synergies the antiproliferative activity of paclitaxel in breast cancer cells via modulating Th1 and Th2 immune response. J. Control. Rel. 196(4), 295–306 (2014). • Preparation and development of nanoemulsion formulation.
  Medline CASGoogle Scholar
• 40. Kim JE, Park YJ. High paclitaxel-loaded and tumor cell-targeting hyaluronan-coated nanoemulsions. Colloids Surf. B Biointerfaces 150, 362–372 (2017).
  Medline CASGoogle Scholar
• 41. Alayoubi AY, Anderson JF, Satyanarayanajois SD, Sylvester PW, Nazzal S. Concurrent delivery of tocotrienols and simvastatin by lipid nanoemulsions potentiates their antitumor activity against human mammary adenocarcenoma cells. Eur. J. Pharm. Sci. 48(3), 385–392 (2013).
  Medline CASGoogle Scholar
• 42. Sharif HR, Williams PA, Sharif MK et al. Influence of OSA-starch on the physico chemical characteristics of flax seed oil-eugenol nanoemulsions. Food Hydrocoll. 66, 365–377 (2017).
  CASGoogle Scholar
• 43. Singh Y, Durga Rao Viswanadham KK, Kumar Jajoriya A et al. Click biotinylation of PLGA template for biotin receptor oriented delivery of doxorubicin hydrochloride in 4T1 cell-induced breast cancer. Mol. Pharm. 14(8), 2749–2765 (2017). • Highlights various aspects of in vitro cellular study.
  Medline CASGoogle Scholar
• 44. Dubey RD, Alam N, Saneja A et al. Development and evaluation of folate functionalized albumin nanoparticles for targeted delivery of gemcitabine. Int. J. Pharm. 492(1–2), 80–91 (2015).
  Medline CASGoogle Scholar
• 45. Gupta S, Chaurasia M, Sharma K et al. Pluronic F-127 stabilised docetaxel nanocrystals improve apoptosis by mitochondrial depolarization in breast cancer cells: pharmacokinetics and toxicity assessment. J. Biomed. Nanotechnol. 11(10), 1747–1763 (2015).
  MedlineGoogle Scholar
• 46. Ye J, Dong W, Yang Y et al. Vitamin E-rich nanoemulsion enhances the antitumor efficacy of low-dose paclitaxel by driving Th1 immune response. Pharm. Res. 34(6), 1244–1254 (2017).
  Medline CASGoogle Scholar
• 47. Dubey RD, Klippstein R, Wang JTW et al. Novel hyaluronic acid conjugates for dual nuclear imaging and therapy in CD44-expressing tumors in mice in vivo. Nanotheranostics 1(1), 59–79 (2017).
  MedlineGoogle Scholar
• 48. Sharma S, Verma A, Singh J et al. Vitamin B6 tethered endosomal pH responsive lipid nanoparticles for triggered intracellular release of doxorubicin. ACS Appl. Mater. Interfaces 8(44), 30407–30421 (2016).
  Medline CASGoogle Scholar
• 49. Liu Y, Zhang X, Zhou M, Nan X, Chen X, Zhang X. Mitochondrial-targeting lonidamine-doxorubicin nanoparticles for synergistic chemotherapy to conquer drug resistance. ACS Appl. Mater. Interfaces 9(50), 43498–43507 (2017).
  Medline CASGoogle Scholar
• 50. Liu HN, Guo NN, Wang TT et al. Mitochondrial targeted doxorubicin-triphenylphosphonium delivered by hyaluronic acid modified and pH responsive nanocarriers to breast tumor: in vitro and in vivo studies. Mol. Pharm. 15(3), 882–891 (2018).
  MedlineGoogle Scholar
• 51. Bielski ER, Zhong Q, Brown M, da Rocha SRP. Effect of the conjugation density of triphenylphosphonium cation on the mitochondrial targeting of poly(amidoamine) dendrimers. Mol. Pharm. 12(8), 3043–3053 (2015).
  Medline CASGoogle Scholar
• 52. Ma P, Chen J, Bi X et al. Overcoming multidrug resistance through the GLUT1-mediated and enzyme-triggered mitochondrial targeting conjugate with redox-sensitive paclitaxel release. ACS Appl. Mater. Interfaces 10(15), 12351–12363 (2018).
  Medline CASGoogle Scholar
• 53. Neophytou CM, Constantinou C, Papageorgis P, Constantinou AI. D-alpha-tocopheryl polyethylene glycol succinate (TPGS) induces cell cycle arrest and apoptosis selectively in Survivin-overexpressing breast cancer cells. Biochem. Pharmacol. 89(1), 31–42 (2014).
  Medline CASGoogle Scholar
• 54. Guzzarlamudi S, Singh PK, Pawar VK et al. Synergistic chemotherapeutic activity of curcumin bearing methoxypolyethylene glycol-g-linoleic acid based micelles on breast cancer cells. J. Nanosci. Nanotechnol. 16(4), 4180–4190 (2016).
  Medline CASGoogle Scholar
• 55. Shukla RP, Urandur S, Banala VT et al. Development of putrescine anchored nano-crystalsomes bearing doxorubicin and oleanolic acid: deciphering their role in inhibiting metastatic breast cancer. Biomater. Sci. 9(5), 1779–1794 (2021).
  Medline CASGoogle Scholar
• 56. Banerjee M, Chattopadhyay S, Choudhuri T et al. Cytotoxicity and cell cycle arrest induced by andrographolide lead to programmed cell death of MDA-MB-231 breast cancer cell line. J. Biomed. Sci. 23(1), 1–16 (2016).
  MedlineGoogle Scholar
• 57. Sharma S, Verma A, Pandey G, Mittapelly N, Mishra PR. Investigating the role of pluronic-g-cationic polyelectrolyte as functional stabilizer for nanocrystals: impact on paclitaxel oral bioavailability and tumor growth. Acta Biomater. 26, 169–183 (2015).
  Medline CASGoogle Scholar
• 58. Meher JG, Dixit S, Pathan DK et al. Paclitaxel-loaded TPGS enriched self-emulsifying carrier causes apoptosis by modulating survivin expression and inhibits tumour growth in syngeneic mammary tumours. Artif. Cells Nanomed. Biotechnol. 46(sup3), S344–S358 (2018).
  Medline CASGoogle Scholar
• 59. Sharma S, Singh J, Verma A et al. Hyaluronic acid anchored paclitaxel nanocrystals improves chemotherapeutic efficacy and inhibits lung metastasis in tumor-bearing rat model. RSC Adv. 6(77), 73083–73095 (2016).
  CASGoogle Scholar
• 60. Banala VT, Urandur S, Sharma S et al. Targeted co-delivery of the aldose reductase inhibitor epalrestat and chemotherapeutic doxorubicin: via a redox-sensitive prodrug approach promotes synergistic tumor suppression. Biomater. Sci. 7(7), 2889–2906 (2019). • Highlights the importance of antitumor efficacy studies of developed nanoformulations.
  Medline CASGoogle Scholar
• 61. Gairola S, Ram C, Syed AM et al. Nootkatone confers antifibrotic effect by regulating the TGF-β/Smad signaling pathway in mouse model of unilateral ureteral obstruction. Eur. J. Pharmacol. 910, 174479 (2021). • Highlights the importance of antitumor efficacy studies of developed nanoformulations.
  Medline CASGoogle Scholar
• 62. Banala VT, Sharma S, Barnwal P et al. Synchronized ratiometric codelivery of metformin and topotecan through engineered nanocarrier facilitates in vivo synergistic precision levels at tumor site. Adv. Healthc. Mater. 7(19), 1–14 (2018). •• Describes strategies for live animal imaging.
  Google Scholar
• 63. Nagahara R, Onda N, Yamashita S et al. Fluorescence tumor imaging by i.v. administered indocyanine green in a mouse model of colitis-associated colon cancer. Cancer Sci. 109(5), 1638–1647 (2018).
  Medline CASGoogle Scholar
• 64. Onda N, Kimura M, Yoshida T, Shibutani M. Preferential tumor cellular uptake and retention of indocyanine green for in vivo tumor imaging. Int. J. Cancer 139(3), 673–682 (2016).
  Medline CASGoogle Scholar
• 65. Pandey G, Mittapelly N, Valicherla GR et al. P-gp modulatory acetyl-11-keto-β-Boswellic acid based nanoemulsified carrier system for augmented oral chemotherapy of docetaxel. Colloids Surf. B Biointerfaces 155, 276–286 (2017).
  Medline CASGoogle Scholar
• 66. Ciccolini J, Catalin J, Blachon MF, Durand A. Rapid high-performance liquid chromatographic determination of docetaxel (Taxotere) in plasma using liquid-liquid extraction. J. Chromatogr. B Biomed. Sci. Appl. 759(2), 299–306 (2001). •• Chromatographic resolution of paclitaxel.
  Medline CASGoogle Scholar